Cell & Gene Therapy
FDA grants RMAT designation to Taysha’s Rett syndrome gene therapyÂ
The FDA has awarded the designation following a review of initial safety and efficacy data from two Phase I/II clinical trials.
The FDA has awarded the designation following a review of initial safety and efficacy data from two Phase I/II clinical trials.